echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Haisco's application for clinical trial of HSK36273 for injection has been accepted

    Haisco's application for clinical trial of HSK36273 for injection has been accepted

    • Last Update: 2022-02-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 17, Hisco announced that it had recently received the "Notice of Acceptance" issued by the State Drug Administration, and that HSK36273 for injection was approved for clinical trials


    HSK36273 for injection is an intravenous anticoagulant drug EP-7041 introduced by Haisco in the early stage.


    Hemodialysis is one of the treatments for acute and chronic renal failure


    At present, the drugs commonly used in clinical anticoagulation therapy mainly include vitamin K antagonists, heparin, small molecule heparin, coagulation factor Xa inhibitors, direct thrombin inhibitors and thrombolytics


    HSK36273 is a novel anticoagulant drug that only acts on the intrinsic coagulation pathway, and is expected to solve the bleeding problem in clinical anticoagulation therapy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.